Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

By E. Vilar‐Gomez, Yadina Martínez-Pérez, Luis Calzadilla‐Bertot, A. Torres-Gonzalez, B. Gra-oramas, Licet Gonzalez-Fabian, S. Friedman, M. Diago, M. Romero‐Gomez. Gastroenterology, 2015

2,218 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/300af29b6463e3f2d562faaef9cec2029060da74

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. M. Rinella
3. K. Cusi
4. A. Sanyal
5. L. Adams
6. G. Targher
7. R. Loomba

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. A. Sanyal
4. K. Cusi
5. E. Brunt
6. Shira Zelber-Sagi
7. J. Lavine
8. N. Chalasani

In Hepatology

1. Z. Younossi
2. M. Rinella
3. K. Cusi
4. A. Sanyal
5. Shira Zelber-Sagi
6. E. Brunt
7. Natascha Roehlen
8. E. Crouchet

Citations in the corpus

• Treatment of NAFLD with diet, physical activity and exercise. (2017, methodology): “There was improvement in hepatic steatosis, lobular inflammation, and ballooning in the intervention group; but results showed no improvement in fibrosis in either group.148 In another study on the effect of lifestyle changes in patients with NASH, those who lost 10% or more of total body weight exh”
• The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease (2020, background): “A recent study (n = 293) showed an improvement in liver histology (steatohepatitis) in 58% of those achieving > 5% and in 90% of those achieving weight loss of > 10%, respectively; only the latter demonstrated an improvement in fibrosis stage (in 45%) [190].”
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review (2023, background): “35 Another study showed that lifestyle intervention could result in resolution of SLD in up to 97% of patients.”
• Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. (2019, background): “Resolution of NASH is achieved in 65–90% of patients achieving ≥7% weight loss [128].”
• Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives (2020, background): “In metabolic liver disease, lifestyle changes and bariatric surgery can induce regression of histological fibrosis [231], however, licensed therapeutic compounds for NASH are absent.”